digital therapeutics
Development of the Pear-006 digital therapeutic is a joint collaboration with Novartis.
Earlier this week panelists at the World Medical Innovation Forum talked validation gaps, advantages and the future of digital mental health tools.
The daily-use digital intervention yielded "clinically meaningful" improvement in blood pressure among 172 users.
Commitment to digital health varies across today’s leading pharmas, and many stakeholders are still waiting for the novel treatments to prove themselves with evidence and commercialization success.
The company has plans to work on new, streamlined design systems for the future.
At HXD 2019, a team from Kaiser Permanente described their efforts to build and populate a mental health app ecosystem for their clinicians.
A new report from PwC predicts that new and proposed FDA regulations could open up doors for pharmaceutical companies looking to develop digital tools.
Of note, the deal specifies that Akili will still control the rollout and support of its video game-like therapy through a yet-to-be-seen digital distribution platform.
The nine-month programme is designed to help entrepreneurs addressing pressing health and care challenges scale their businesses.